Bio-Path Holdings (BPTH)
$6.40 0.08 (1.23%)
19:13 EST BPTH Stock Quote Delayed 15 Minutes
Previous Close $6.40
Market Cap 72.58M
PE Ratio -6.88
Volume (Avg. Vol.) 47,900
Day's Range 6.31 - 6.52
52-Week Range 1.84 - 73.52
Dividend & Yield N/A (N/A)
BPTH Stock Predictions, Articles, and Bio-Path Holdings News
- From InvestorPlace
- From the Web
Bio-Path (BPTH) earnings for the biotechnology company's third quarter of 2019 saw BPTH stock taking a wild ride on Friday.
The stock charts of SLB, HBI and OMC have earned a closer technical look headed into today's trading action.
Bio-Path Holdings news about the company not offering additional shares of its stock as previously planned has BPTH up on Monday.
BPTH stock is easily one of 2019's top performers, but you’ve got to look at the whole Bio-Path story before jumping aboard.
Recent Bio-Path Holdings news concerning a clinical update for a Phase 2 trial has BPTH stock flying high as of Wednesday.
Bio-Path (BPTH) stock was up Tuesday after the company announced financial data for 2017 and interim results for a Phase 2 study.
Analysts Offer Insights on Healthcare Companies: Enlivex Therapeutics (NASDAQ: ENLV), Amarin (NASDAQ: AMRN) and Bio-Path Holdings (NASDAQ: BPTH)
From Analyst Ratings
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enlivex Therapeutics (ENLV – Research Report), Amarin (AMRN – Research Report) and Bio-Path Holdings (BPTH – Research Report) with bullish sentiments. Enlivex Therapeutics (ENLV) In a report released today, Ram Selvaraju from H.C. Wainwright initiated coverage with